← Back to Search

Corticosteroid

Adrenocorticotropic Hormone for Proliferative Vitreoretinopathy

Q: How does Adrenocorticotropic Hormone generally ameliorate medical conditions?

The hormone known as ACTH is typically used to treat acute coryza, but it has also been found to help patients with juvenile <a href="https://www.withpower.com/clinical-trials/arthritis">arthritis</a>, optic neuritis, and <a href="https://www.withpower.com/clinical-trials/dermatomyositis">dermatomyositis</a>.

Q: How many participants are eligible for this clinical study?

Affirmative. Clinicaltrials.gov documentation confirms that this clinical trial is still recruiting participants, having been first posted on August 19th 2019 and most recently edited on August 9th 2022. The medical study requires 15 people to be recruited from one site.

Q: Has Adrenocorticotropic Hormone been previously tested in similar experiments?

Presently, there are 9 active studies researching the effects of Adrenocorticotropic Hormone with two trials in their final stages. Of these locations, 104 sites are located across Minneapolis and <a href="https://www.withpower.com/clinical-trials/minnesota">Minnesota</a> while the remaining ones can be found <a href="https://www.withpower.com/clinical-trials/all">all</a> over the world.

Q: Is this research undertaking currently open to enrollment?

Affirmative, the information on clinicaltrials.gov demonstrates that this trial has been in search of volunteers since 19th August 2019 and is still ongoing. A total of 15 subjects are needed from a single site.

Phase < 1

Waitlist Available

Led By Peter A Campochiaro, MD

Research Sponsored by Johns Hopkins University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 1 day after surgery, 1 week after surgery

Awards & highlights

Study Summary

This trial is to study the effects of H.P. Acthar®, an adrenocorticotropic hormone (ACTH) analog, on post-operative proliferative vitreoretinopathy patients. There will be 15 patients enrolled who will either receive H.P. Acthar® or standard of care. Aqueous samples will be taken at different time points to measure levels of albumin and inflammatory cytokines.

Eligible Conditions

Proliferative Vitreoretinopathy

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 1 day after surgery, 1 week after surgery

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 1 day after surgery, 1 week after surgery

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 1 day after surgery, 1 week after surgery for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Secondary outcome measures

Change in best-corrected visual acuity as measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) score in post-operative PVR patients receiving subcutaneous injections of H.P. Acthar® versus controls

Change in mean aqueous levels of TGF-B in post-operative PVR patients receiving subcutaneous injections of H.P. Acthar® versus controls

Change in mean aqueous levels of albumin in post-operative PVR patients receiving subcutaneous injections of H.P. Acthar® versus controls

+5 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: H.P. Acthar ®Experimental Treatment1 Intervention

Subjects will self-administer subcutaneous injections of 80 units of adrenocorticotropic hormone analog starting on post-operative day 1 for twice a week until week 8.

Group II: ControlsActive Control1 Intervention

Subjects will be managed per the standard of care.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Adrenocorticotropic Hormone

2019

Completed Phase 3

~80

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor

2,260 Previous Clinical Trials

14,820,769 Total Patients Enrolled

MallinckrodtIndustry Sponsor

201 Previous Clinical Trials

16,217 Total Patients Enrolled

Peter A Campochiaro, MDPrincipal InvestigatorWilmer Eye Institute, Johns Hopkins School of Medicine

10 Previous Clinical Trials

807 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How does Adrenocorticotropic Hormone generally ameliorate medical conditions?

"The hormone known as ACTH is typically used to treat acute coryza, but it has also been found to help patients with juvenile arthritis, optic neuritis, and dermatomyositis."

Answered by AI

How many participants are eligible for this clinical study?

"Affirmative. Clinicaltrials.gov documentation confirms that this clinical trial is still recruiting participants, having been first posted on August 19th 2019 and most recently edited on August 9th 2022. The medical study requires 15 people to be recruited from one site."

Answered by AI

Has Adrenocorticotropic Hormone been previously tested in similar experiments?

"Presently, there are 9 active studies researching the effects of Adrenocorticotropic Hormone with two trials in their final stages. Of these locations, 104 sites are located across Minneapolis and Minnesota while the remaining ones can be found all over the world."

Answered by AI

Is this research undertaking currently open to enrollment?

"Affirmative, the information on clinicaltrials.gov demonstrates that this trial has been in search of volunteers since 19th August 2019 and is still ongoing. A total of 15 subjects are needed from a single site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)

2019. "Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03727776.